New Group To Resolve 'International Divergence' Posed By EU ATMP Guide
Executive Summary
Pharmaceutical inspectorates around the world are trying to address the divergences between Europe’s good manufacturing practice guideline on gene therapy and tissue-engineered products and the international GMP guideline for such products.
You may also be interested in...
PIC/S Finds A Way To Solve Divergences With EU ATMP Guide
A targeted stakeholder consultation will soon be launched on proposals to split the Pharmaceutical Inspection Co-operation Scheme's existing guide on biological products into two parts so as to focus separately on manufacturing issues specific to gene therapy and tissue-engineered products.
European Commission Finally Delivers On GMP Standards For ATMPs
Following protracted consultations with stakeholders on how best to specify good manufacturing practice standards for advanced therapies, the European Commission has at last published the long-awaited guideline. The industry is now keen to work with EU inspectors and competent authorities to develop a common understanding of the risk-based principles outlined in the final document.
European Commission To ‘Explain And Discuss’ Contentious GMP Guide For ATMPs
The European Commission has agreed to meet with a group representing the world's leading pharmaceutical inspectorates to discuss its concerns about the commission's proposal to relax GMP guidelines for cell and gene therapy products. Industry, hopeful that the commission is finally ready to listen, is looking to share its concerns again as well.